Recent Finacing
Recent Raise
Rubedo Life Sciences develops small‑molecule senolytic prodrugs with its ALEMBIC platform to selectively target senescent, pro‑inflammatory and pro‑fibrotic cells, advancing pulmonary (IPF, COPD), dermatology and oncology programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
